Skip to content

Modulation of Type 1 Cannabinoid Receptor by Cannabis Sativa By-Products and Non-Cannabis Phytomolecules

In 2018, Canada became the first G7 country to legalize Cannabis sativa for non-medical purposes. Despite decades of research and significant legislative and policy advances, our scientific understanding of Cannabis and cannabinoid pharmacology remains quite limited. Gaining a more comprehensive understanding of cannabinoid pharmacology to better shed further light on the beneficial and harmful effects of cannabis is critically important.